Display options
Share it on

Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):227-37. doi: 10.1586/14737167.7.3.227.

Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.

Expert review of pharmacoeconomics & outcomes research

William E Wade, William J Spruill

Affiliations

  1. Professor, University of Georgia, Department of Clinical & Administrative Pharmacy, College of Pharmacy, Athens, GA 30602, USA. [email protected].

PMID: 20528310 DOI: 10.1586/14737167.7.3.227

Abstract

Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby reducing the risk of thrombocytopenia. Clinical trials have repeatedly demonstrated superior efficacy over other anticoagulants as venous thromboembolism prophylaxis and several cost-effectiveness studies have demonstrated cost savings with this drug.

Publication Types